PharmApprove, a leading strategic regulatory, and scientific communications consultancy based in the US, and NDA Group, a european regulatory, pharmacovigilance and Health Technology Assessment (HTA) consultancy, announced a new collaboration to provide the life science industry with integrated global regulatory, scientific and market access communications solutions.
PharmApprove has over 16 years of experience providing strategic and tactical support helping life science companies prepare for health authority interactions, deliver compelling regulatory and scientific arguments before US advisory committees, and making the persuasive value case to payers and HTAs. NDA Group has been at the forefront of providing strategic and operational regulatory, HTA and pharmacovigilance guidance for the last 18 years. The companies plan to offer aligned services in the following areas:
- Global integrated product development strategy, simultaneous filing support, and strategic scientific, regulatory advice through all stages of development;
- Scientific communications to help companies make the strongest, most persuasive case to regulatory and advisory audiences, both verbally and visually;
- Preparation for global milestone meetings and interactions with key decision makers.